Search results
Showing 76 to 90 of 216 results for withdrawal
guidance Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults...
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (HTG251)
Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.
View recommendations for HTG251Show all sections
Sections for HTG251
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
guidance Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults...
guidance Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults...
Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)
Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.
View recommendations for HTG161Show all sections
Sections for HTG161
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.